Keikha Masoud, Karbalaei Mohsen
Antimicrobial Resistance Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Microbiology and Virology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Department of Microbiology and Virology, School of Medicine, Jiroft University of Medical Sciences, Jiroft, Iran.
Microb Pathog. 2022 May;166:105518. doi: 10.1016/j.micpath.2022.105518. Epub 2022 Apr 8.
The clinical relevance of Helicobacter heilmannii (H. heilmannii) infection in patients with upper gastrointestinal diseases is not yet fully understood. The main purpose of this study was to evaluate the clinical, endoscopic, histopathological, and therapeutic features of H. heilmannii.
To retrieve the relevant studies, we conducted a comprehensive systematic search of global databases such as the ISI Web of Science, PubMed, Scopus, Embase, and Google Scholar. After confirming the studies based on the inclusion criteria statistical analysis was performed using Comprehensive Meta-Analysis software.
In our study, the prevalence of infection with H. heilmannii was measured at 1.9% (95% CI: 0.8-4.2). The prevalence of H. heilmannii in Asian population was higher than Western countries (3.1% vs. 1.2%, respectively). Interestingly, the frequency of coinfection with both H. pylori and H. heilmannii was 15.4% (95% CI: 5.2-37.6). The most common endoscopic findings were chronic gastritis, hyperplasia, and erosion. In addition, our results showed that in people infected with this bacterium, gastric inflammation is typically chronic, focal, and less active than Helicobacter pylori (H. pylori) gastritis. Conventional treatment of H. pylori can lead to the eradication of H. heilmannii.
In general, H. heilmannii infection is significantly associated with mild chronic gastritis and can be treated with standard anti-H. pylori treatment.
幽门螺杆菌（H. heilmannii）感染在上消化道疾病患者中的临床相关性尚未完全明确。本研究的主要目的是评估H. heilmannii的临床、内镜、组织病理学及治疗特征。
为检索相关研究，我们对ISI Web of Science、PubMed、Scopus、Embase和谷歌学术等全球数据库进行了全面系统的检索。根据纳入标准确认研究后，使用综合荟萃分析软件进行统计分析。
在我们的研究中，H. heilmannii感染的患病率为1.9%（95%置信区间：0.8 - 4.2）。亚洲人群中H. heilmannii的患病率高于西方国家（分别为3.1%和1.2%）。有趣的是，幽门螺杆菌（H. pylori）和H. heilmannii双重感染的频率为15.4%（95%置信区间：5.2 - 37.6）。最常见的内镜表现为慢性胃炎、增生和糜烂。此外，我们的结果表明，感染这种细菌的人群中，胃部炎症通常为慢性、局灶性，且比幽门螺杆菌（H. pylori）胃炎的活动性更低。传统的幽门螺杆菌治疗可导致H. heilmannii被根除。
总体而言，H. heilmannii感染与轻度慢性胃炎显著相关，可采用标准的抗幽门螺杆菌治疗。
